LIF and hepatocellular carcinoma: Our findings provide new insights into the role of LIF/p38MAPK/p62‐regulated mitophagy in HCC tumorigenesis and shed light on exploiting the first established LIF inhibitor CVB‐D as a small‐molecule drug candidate for future HCC therapeutics.